⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
AVTX News
Avalo Therapeutics, Inc. Common Stock
Form 8-K
sec.gov
AVTX
Avalo Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates
globenewswire.com
AVTX
Form 8-K
sec.gov
AVTX
Avalo Therapeutics Announces Pricing of $375 Million Public Offering
globenewswire.com
AVTX
Avalo Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
globenewswire.com
AVTX
Form 8-K
sec.gov
AVTX
Avalo Therapeutics Achieves Positive Topline Results in Phase 2 LOTUS Trial of Abdakibart (AVTX-009) in Moderate to Severe Hidradenitis Suppurativa
globenewswire.com
AVTX
Ashvattha Therapeutics Announces Presentations Highlighting Mechanism of Action for Migaldendranib in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration
businesswire.com
AVTX
Form 8-K
sec.gov
AVTX
Avalo Therapeutics Purchases Optional Milestone Buyout
globenewswire.com
AVTX